TW201615226A - 代謝性疾病藥物臨床新應用 - Google Patents

代謝性疾病藥物臨床新應用 Download PDF

Info

Publication number
TW201615226A
TW201615226A TW104134965A TW104134965A TW201615226A TW 201615226 A TW201615226 A TW 201615226A TW 104134965 A TW104134965 A TW 104134965A TW 104134965 A TW104134965 A TW 104134965A TW 201615226 A TW201615226 A TW 201615226A
Authority
TW
Taiwan
Prior art keywords
drug
cancer
group
drugs
metabolic disease
Prior art date
Application number
TW104134965A
Other languages
English (en)
Inventor
陳丘泓
莊秀美
蕭乃文
梁瑞岳
筱彤 陳
Original Assignee
朗齊生物醫學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 朗齊生物醫學股份有限公司 filed Critical 朗齊生物醫學股份有限公司
Publication of TW201615226A publication Critical patent/TW201615226A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

本發明提供多種代謝性疾病藥物的臨床新應用。該多種代謝性疾病藥物皆是衛生署核准上市的代謝性疾病藥物。本發明提供多種代謝性疾病藥物能有效的抑制不同類型的癌細胞。

Description

代謝性疾病藥物臨床新應用
本發明係為多種代謝性疾病藥物的新適應症之應用，尤其該多種藥物為衛生署核准上市的藥物且具有抑制多種癌症之用途。
癌症長期高居全球死因之首，且罹患癌症人數更是逐年攀升，因此治療癌症儼然成為重要的課題。癌症的治療可區分為手術治療、放射線治療、化學治療及標靶治療。
一般來說，癌症藥物治療無論是化學治療或標靶治療，目的多是讓癌細胞無法複製、分裂，來阻斷腫瘤的蔓延擴張。在臨床治療選擇上，通常會結合一到數種化療藥物以及標靶治療，希望能藉由不同機制來殺死癌細胞以提高治療效果，但事實上，還是常遇到患者對於治療藥物的反應不佳。進一步，許多癌細胞相繼產生抗藥性，使藥物的使用成效大幅降低，最終導致癌症治療失敗。
儘管如此，癌症藥物開發依然是重要的醫學議題， 開發過程必須經過繁複的臨床前試驗才能進入臨床試驗。根據統計，平均每一萬個新藥約只有五個能夠進入第一期臨床試驗。此外，除了藥物本身是否能大量製造的難題外，還需克服藥物安全性、病人篩選、試用劑量等問題，即便藥物已經通過FDA的核准並上市，亦有可能因上市後於人體發現不良反應而強制下架回收，由此可見藥物開發具有一定的困難程度。
有鑑於此，本發明係針對通過臨床實驗且對人體無不良反應的多種藥物進行新適應症的研發，而達到老藥新用的目標。
發明人依據長年的研究經驗，證實癌症細胞與正常細胞相比，具有不同的表現性狀、型態上的差異或是作用機轉的變化，而每一種癌症細胞所在的位置不同、變異的狀態又與所處的環境有關，因此發明人認為癌細胞亦可視為另一種代謝異常的細胞，而提出使用代謝性疾病藥物抑制癌症細胞的發明概念並且進行實驗。
本發明提供一種製備抑制癌症之醫藥組合物之方法，其中該醫藥組合物係包含一有效劑量的一代謝性疾病藥物及一藥物可接受的鹽類。
本發明所述代謝性疾病藥物是FDA所認可的用藥， 且於人體或動物體中使用數十年，具有大量藥物機轉及人體研究成果的資料，因此，若應用在癌症方面，這項新發展會更省時、減少成本，也能和其他治療方式結合來提高效果。此外，現今癌症藥物費用動輒上萬至數百萬元，而本發明所述代謝性疾病藥物對癌症細胞具有治療功效，因此對於無法負擔昂貴治療的患者們，這些便宜而歷史悠久的藥物，會帶來新希望。
本發明一實施例中，其中該代謝性疾病藥物係選自由降血糖劑、強肝劑、痛風治療劑、腎臟透析用藥、解毒劑、酵素製劑及其他代謝性疾病用藥等藥物。
本發明所述降血糖劑係為市售的口服降血糖藥，可區分為六類：一、磺醯尿素類：刺激胰臟分泌較多量的胰島素，降血糖效果佳；二、雙胍類：抑制小腸對糖及氨基酸的吸收，抑制肝臟製造葡萄糖；三、唑烷二酮類：降低胰島素阻抗性，又稱為胰島素增敏劑；四、美格替耐類：刺激胰臟分泌胰島素，特點是藥效快，作用時間短，主要為肝代謝；五、α型雙糖分解脢抑制劑：抑制腸道內糖類分解，減少糖類的吸收，主要用來控制飯後血糖濃度；六、雙胜肽蛋白水解酶抑制劑：促進腸泌素激素作用，較不易引起低血糖，控制飯後血糖效果佳。
本發明一實施例中，其中該降血糖劑係選自由血糖 平(Glibenclamide)、滅糖尿(Minidiab)、岱蜜克龍(Diamicron)、醣祿錠(Acarbose)、瑪爾胰錠(Glimepiride)、庫魯化錠(Glucophage)、口服維他命A酸(Isotretinoin)、奥美拉唑(Omeprazole(Prilosec))、梵蒂雅錠(Avandia)、諾和隆錠(Novonorm)、佳糖維(Januvia)、使糖立釋膜衣錠(Starlix)、糖祿錠(Glucobay)、Orlistat(Alli、Xenical)、Amiloride hydrochloride(Midamor)、Aspartame、吡格列酮(Pioglitazone hydrochloride(Actos))、Roxithromycin、Phenformin hydrochloride、Vildagliptin、Gliquidone、Voglibose、Cysteamine HCl、Cepharanthine及Tolazamide所組成之藥物。
本發明一實施例中，其中該強肝劑藥物係選自由馬洛替酯片(Malotilate)、思利馬林膠囊本(SILYMARIN)、GLUTATHION REDUCED、維他命B12(Vitamin B12)、溫諾平(Vinorelbine(Navelbine))、Monobenzone(Benoquin)、Niacin(Nicotinic acid)、L-Glutamine、Captopril(Capoten)、Balofloxacin及Tolvaptan所組成之藥物。
本發明一實施例中，其中該痛風治療劑係選自由五洲痛立安膠囊(ACEO)、優諾錠(Benzbromarone)及Benemid所組成之藥物。
本發明一實施例中，其中該腎臟透析用藥物係選自 由ARTIFICIAL、Gemcitabine(Gemzar)、Ranitidine(Zantac)、Xylose及Levosimendan所組成之藥物。
本發明一實施例中，其中該解毒劑藥物係選自由碳酸氫鈉錠(Sodium bicarbonate)、氯磷錠(PRALIDOXIME CHLORIDE)、帕米膦酸鹽(Pamidronate Disodium)及Ribavirin所組成之藥物。
本發明一實施例中，其中該酵素製劑藥物係選自由安病疾錠(AMBEZIM)、Nizatidine、維他命B12(Vitamin B12)、Lisinopril、Bezafibrate及Doxofylline所組成之藥物。
本發明一實施例中，其中該其他代謝性疾病用藥係選自由昇骨卓(Risedronate sodium)、服瘤停注射劑(Pralatrexate(Folotyn))、福善美(Alendronate(Fosamax))、熊二醇(Ursodiol(ActigalUrso))、Risedronic acid(Actonel)、Mecarbinate、Licofelone、Manidipine、Allylthiourea、Tolcapone及Chlorzoxazone所組成之藥物。
本發明一實施例中，其中該癌症係選自由肺癌、腸道癌、大腸直腸癌、前列腺癌、膀胱癌、子宮頸癌、乳癌及血癌所組成之群組。
本發明一實施例中，其中該有效劑量係為20mg/kg/day-500mg/kg/day。
第一圖顯示本發明代謝性疾病用藥應用於抑制各種癌細胞的分析結果
建立細胞株
請參考表一，將不同類型的癌症細胞株進行繼代培養，計算細胞數目後，回種2*106細胞數，然後加入培養該細胞株之培養液補至體積為10ml，繼續培養2-3天。之後將細胞計數，並分裝至96孔盤，其中每孔的細胞數目固定為3000顆，且體積為100ul。
細胞存活分析方法
將96孔盤中原有的培養液吸掉，每孔加入濃度10um、體積100ul的市售代謝性疾病用藥，放置72小時後，每孔再加入100ul已稀釋的WST-1試劑，該稀釋比例為培養液與WST-1原液的體積比為9：1，最後每個孔盤的總體積為200ul，然後將96孔盤放置於37度30~90分鐘，利用Elisa reader於OD450偵測吸光值，並計算各癌症細胞株之存活率。
代謝性疾病用藥物應用於抑制癌細胞分析結果
本發明所述代謝性疾病用藥可依治療的疾病種類分為降血糖劑、強肝劑、痛風治療劑、腎臟透析用藥、解毒劑、酵素製劑及其他代謝性疾病用藥等藥物。
請參考表二，實驗結果顯示Pamidronate Disodium、Ranitidine(Zantac)、Licofelone、Ribavirin(Copegus)、Roxithromycin(Roxl-150)、Tolvaptan(OPC-41061)、Rivaroxaban(Xarelto)、Mepivacaine HCl、Clofibric acid並無法有效的抑制肺癌細胞株(H1650、A549)、胃癌細胞株(AGS、MKN-45)、肝癌細胞株(HepG2)、直腸癌細胞株(HCT116、LoVo)、皮膚癌細胞株(A375)、子宮頸癌細胞株(HeLa)、前列腺癌細胞株(PC3)、膀胱癌細胞株(TSGH-8301)、乳癌細胞株(MCF7)及血癌細胞株(HL-60)的生長。
而其他代謝性疾病用藥對於各種癌症細胞的抑制效果也不盡相同，如下表三所示，表三中的數值係以IC50(半抑制濃度，half maximal inhibitory concentration)表示，灰色標記表示該代謝性疾病藥物對於該細胞株有明顯抑制的功效。
實驗結果證實馬洛替酯(Malotilate)、亞葉酸鈣制(Leucovorin Calcium)、醣祿錠(Acarbose)、瑪爾胰錠(Glimepiride)、口服維他命A酸(Isotretinoin)、奥美拉唑(Omeprazole(Prilosec))、昇骨卓(Risedronate sodium)、服瘤停注射劑(Pralatrexate(Folotyn))、溫諾平(Vinorelbine(Navelbine))、熊二醇(Ursodiol(Actigal Urso))、Monobenzone(Benoquin)、Gemcitabine(Gemzar)、Niacin(Nicotinic acid)、L-Glutamine、維他命B12(Vitamin B12)、Aspartame、吡格列酮(Pioglitazone hydrochloride(Actos))、Captopril(Capoten)、Balofloxacin、Mecarbinate、Lisinopril(Zestril)、Bazedoxifene HCl、Donepezil HCl(Aricept)、Phenformin hydrochloride、Scopine、Mifepristone(Mifeprex)、Noradrenaline bitartrate monohydrate(Levophed)、Vildagliptin(LAF-237)、Pravastatin sodium、Flumequine、Probenecid(Benemid)、Amprolium HCl、氯唑沙宗(Chlorzoxazone)、降血脂劑(Bezafibrate)、多索茶鹼(Doxofylline)、千金藤素(Cepharanthine)等藥物對於肺癌症細胞有明顯的抑制效果。
實驗結果證實亞葉酸鈣制(Leucovorin Calcium)、醣祿錠(Acarbose)、奥美拉唑(Omeprazole(Prilosec))、昇骨卓(Risedronate sodium)、服瘤停注射劑(Pralatrexate(Folotyn))、溫諾平(Vinorelbine(Navelbine))、福善美(Alendronate(Fosamax))、Orlistat(Alli,Xenical)、熊二醇(Ursodiol(Actigal Urso))、Monobenzone(Benoquin)、Gemcitabine(Gemzar)、Amiloride hydrochloride(Midamor)、Risedronic acid(Actonel)、Balofloxacin、Mecarbinate、Lisinopril(Zestril)、Xylose、Bazedoxifene HCl、心得適(Levosimendan)、Donepezil HCl(Aricept)、 Vildagliptin(LAF-237)、Pravastatin sodium、Flumequine、Allylthiourea、Tolcapone、Probenecid(Benemid)、Amprolium HCl、氯唑沙宗(Chlorzoxazone)、降血脂劑(Bezafibrate)、多索茶鹼(Doxofylline)、千金藤素(Cepharanthine)等藥物對於胃癌症細胞有明顯的抑制效果。
實驗結果證實Probenecid(Benemid)藥物對於肝癌症細胞有明顯的抑制效果。
實驗結果證實瑪爾胰錠(Glimepiride)、服瘤停注射劑(Pralatrexate(Folotyn))、溫諾平(Vinorelbine(Navelbine))、Monobenzone(Benoquin)、Risedronic acid(Actonel)、吡格列酮(Pioglitazone hydrochloride(Actos))、Captopril(Capoten)、Balofloxacin、Mecarbinate、Lisinopril(Zestril)、Donepezil HCl(Aricept)、Gliquidone、Flumequine、Clodronate Disodium、氯唑沙宗(Chlorzoxazone)、降血脂劑(Bezafibrate)、多索茶鹼(Doxofylline)等藥物對於結腸癌症細胞有明顯的抑制效果。
實驗結果證實瑪爾胰錠(Glimepiride)、奥美拉唑(Omeprazole(Prilosec))、昇骨卓(Risedronate sodium)、服瘤停注射劑(Pralatrexate(Folotyn))、溫諾平(Vinorelbine(Navelbine))、Monobenzone(Benoquin)、Gemcitabine(Gemzar)、Bazedoxifene HCl、Donepezil HCl(Aricept)、Mifepristone(Mifeprex)、Noradrenaline bitartrate monohydrate(Levophed)、Bufexamac、Vildagliptin(LAF-237)、Sodium Picosulfate、Tolcapone、Probenecid(Benemid)、氯唑沙宗(Chlorzoxazone)、降血脂劑(Bezafibrate)、多索茶鹼(Doxofylline)、千金藤素(Cepharanthine)等藥物對於皮膚癌症細胞有明顯的抑制效果。
實驗結果證實Monobenzone(Benoquin)、L-Glutamine、Balofloxacin、Mecarbinate、Lisinopril(Zestril)、Bazedoxifene HCl、心得適(Levosimendan)、Donepezil HCl(Aricept)、Phenytoin sodium(Dilantin)、氯唑沙宗(Chlorzoxazone)、多索茶鹼(Doxofylline)、千金藤素(Cepharanthine)等藥物對於子宮頸癌症細胞有明顯的抑制效果。
實驗結果證實服瘤停注射劑(Pralatrexate(Folotyn))、溫諾平(Vinorelbine(Navelbine))、熊二醇(Ursodiol(Actigal Urso))、Monobenzone(Benoquin)、Nizatidine、維他命B12(Vitamin B12)、吡格列酮(Pioglitazone hydrochloride(Actos))、Captopril(Capoten)、Balofloxacin、Mecarbinate、Lisinopril(Zestril)、Donepezil HCl(Aricept)、Doxycycline HCl、Allylthiourea、Sodium Picosulfate、Tolcapone、Probenecid(Benemid)、氯唑沙宗(Chlorzoxazone)、降血脂劑(Bezafibrate)、多索茶鹼(Doxofylline)、千金藤素(Cepharanthine)等藥物對於前列腺癌症細胞有明顯的抑制效果。
實驗結果證實亞葉酸鈣制(Leucovorin Calcium)、醣祿錠(Acarbose)、服瘤停注射劑(Pralatrexate(Folotyn))、溫諾平(Vinorelbine(Navelbine))、福善美(Alendronate(Fosamax))、Orlistat(Alli,Xenical)、熊二醇(Ursodiol(Actigal Urso))、Monobenzone(Benoquin)、Gemcitabine(Gemzar)、Balofloxacin、Mecarbinate、Lisinopril(Zestril)、Xylose、心得適(Levosimendan)、Donepezil HCl(Aricept)、Manidipine(Manyper)、Phenformin hydrochloride、Scopine、Tolcapone、Probenecid(Benemid)、氯唑沙宗(Chlorzoxazone)、降血脂 劑(Bezafibrate)、多索茶鹼(Doxofylline)、千金藤素(Cepharanthine)等藥物對於膀胱癌症細胞有明顯的抑制效果。
實驗結果醣祿錠(Acarbose)、昇骨卓(Risedronate sodium)、福善美(Alendronate(Fosamax))、Orlistat(Alli,Xenical)、熊二醇(Ursodiol(Actigal Urso))、Monobenzone(Benoquin)、Niacin(Nicotinic acid)、L-Glutamine、Nizatidine、維他命B12(Vitamin B12)、Aspartame、吡格列酮(Pioglitazone hydrochloride(Actos))、Captopril(Capoten)、Balofloxacin、Mecarbinate、Lisinopril(Zestril)、Bazedoxifene HCl、Flumequine、Voglibose、Clodronate Disodium、氯唑沙宗(Chlorzoxazone)、降血脂劑(Bezafibrate)、多索茶鹼(Doxofylline)、千金藤素(Cepharanthine)、Amprolium HCl等藥物對於乳腺癌症細胞有明顯的抑制效果。
實驗結果證實溫諾平(Vinorelbine(Navelbine))、Gemcitabine(Gemzar)、Bazedoxifene HCl、Manidipine(Manyper)、Phenformin hydrochloride等藥物對於白血病細胞有明顯的抑制效果。
請參考第一圖，由實驗結果可知，代謝性藥物包括Acarbose、Risedronate sodium、Risedronate sodium、Pralatrexate(Folotyn)、Vinorelbine(Navelbine)、Ursodiol(Actigal Urso)、Monobenzone(Benoquin)、Gemcitabine(Gemzar)、Balofloxacin、Mecarbinate、Lisinopril(Zestril)、Bazedoxifene HCl、Donepezil HCl(Aricept)、Phenformin hydrochloride、Probenecid(Benemid)、Chlorzoxazone、Bezafibrate、Doxofylline、Cepharanthine對於不同類型的癌症細胞均有明顯的抑制效果。
重複性實驗
依據表三所示結果，針對癌症細胞株有效之藥物進行重覆性實驗，其結果如表四所示。
而實驗設計的結果顯示代謝性疾病藥物對正常細胞沒有或僅有微小的毒性，但至於代謝性疾病用藥在正常細胞與腫瘤細胞之間是否具有選擇性的影響，還待更多的研究釐清，且並非所有的代謝性疾病用藥在相同的條件下均能有效的抑制腫瘤細胞。
上列詳細說明係針對本發明之一可行實施例之具體說明，惟該實施例並非用以限制本發明之專利範圍，凡未脫離本發明技藝精神所為之等效實施或變更，均應包含於本發明之專利範圍中。

Claims (11)

  1. 一種製備抑制癌症之醫藥組合物之方法，其中該醫藥組合物係包含一有效劑量的一代謝性疾病藥物及一藥物可接受的鹽類。
  2. 如申請專利範圍第1項所述之方法，其中該代謝性疾病藥物係選自由降血糖劑、強肝劑、痛風治療劑、腎臟透析用藥、解毒劑、酵素製劑及其他代謝性疾病用藥所組成之群組藥物。
  3. 如申請專利範圍第2項所述之方法，其中該降血糖劑係選自由血糖平(Glibenclamide)、滅糖尿(Minidiab)、岱蜜克龍(Diamicron)、醣祿錠(Acarbose)、瑪爾胰錠(Glimepiride)、庫魯化錠(Glucophage)、口服維他命A酸(Isotretinoin)、奥美拉唑(Omeprazole(Prilosec))、梵蒂雅錠(Avandia)、諾和隆錠(Novonorm)、佳糖維(Januvia)、使糖立釋膜衣錠(Starlix)、糖祿錠(Glucobay)、Orlistat(Alli、Xenical)、Amiloride hydrochloride(Midamor)、Aspartame、吡格列酮(Pioglitazone hydrochloride(Actos))、Roxithromycin、Phenformin hydrochloride、Vildagliptin、Gliquidone、Voglibose、Cysteamine HCl、Cepharanthine及Tolazamide所組成之藥物。
  4. 如申請專利範圍第2項所述之方法，其中該強肝劑藥物係選自由馬洛替酯片(Malotilate)、思利馬林膠囊本(SILYMARIN)、GLUTATHION REDUCED、維他命B12(Vitamin B12)、溫諾平(Vinorelbine(Navelbine))、Monobenzone(Benoquin)、Niacin(Nicotinic acid)、L-Glutamine、Captopril(Capoten)、Balofloxacin及Tolvaptan所組成之藥物。
  5. 如申請專利範圍第2項所述之方法，其中該痛風治療劑藥物係選自由五洲痛立安膠囊(ACEO)、優諾錠(Benzbromarone)及Benemid所 組成之藥物。
  6. 如申請專利範圍第2項所述之方法，其中該腎臟透析用藥藥物係選自由ARTIFICIAL、Gemcitabine(Gemzar)、Ranitidine(Zantac)、Xylose及Levosimendan所組成之藥物。
  7. 如申請專利範圍第2項所述之方法，其中該解毒劑藥物係選自由碳酸氫鈉錠(Sodium bicarbonate)、氯磷錠(PRALIDOXIME CHLORIDE)、帕米膦酸鹽(Pamidronate Disodium)及Ribavirin所組成之藥物。
  8. 如申請專利範圍第2項所述之方法，其中該酵素製劑藥物係選自由安病疾錠(AMBEZIM)、Nizatidine、維他命B12(Vitamin B12)、Lisinopril、Bezafibrate及Doxofylline所組成之藥物。
  9. 如申請專利範圍第2項所述之方法，其中該其他代謝性疾病用藥係選自由昇骨卓(Risedronate sodium)、服瘤停注射劑(Pralatrexate(Folotyn))、福善美(Alendronate(Fosamax))、熊二醇(Ursodiol(ActigalUrso))、Risedronic acid(Actonel)、Mecarbinate、Licofelone、Manidipine、Allylthiourea、Tolcapone及Chlorzoxazone所組成之藥物
  10. 如申請專利範圍第1項所述之方法，其中該癌症係選自由肺癌、腸道癌、大腸直腸癌、前列腺癌、膀胱癌、子宮頸癌、乳癌及血癌所組成之群組。
  11. 如申請專利範圍第1項所述之方法，其中該有效劑量係為20mg/kg/day-500mg/kg/day。
TW104134965A 2014-10-24 2015-10-23 代謝性疾病藥物臨床新應用 TW201615226A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462068298P 2014-10-24 2014-10-24

Publications (1)

Publication Number Publication Date
TW201615226A true TW201615226A (zh) 2016-05-01

Family

ID=55760314

Family Applications (21)

Application Number Title Priority Date Filing Date
TW104134942A TW201615195A (zh) 2014-10-24 2015-10-23 阿那格雷藥物應用於癌症治療
TW104134956A TW201615196A (zh) 2014-10-24 2015-10-23 山喜多藥物應用於癌症治療
TW104134959A TW201615223A (zh) 2014-10-24 2015-10-23 驅蟲藥臨床新應用
TW104134960A TW201615191A (zh) 2014-10-24 2015-10-23 氨氯地平藥物應用於癌症治療
TW104134936A TWI621434B (zh) 2014-10-24 2015-10-23 千憂解藥物應用於癌症治療
TW104134944A TW201615219A (zh) 2014-10-24 2015-10-23 呼吸系統疾病用藥臨床新應用
TW104134950A TWI663969B (zh) 2014-10-24 2015-10-23 莫諾苯宗藥物應用於癌症治療
TW104134946A TWI663984B (zh) 2014-10-24 2015-10-23 神經疾病用藥臨床新應用
TW104134940A TW201615186A (zh) 2014-10-24 2015-10-23 脫克鈣藥物應用於癌症治療
TW104134966A TW201615194A (zh) 2014-10-24 2015-10-23 氨苯蝶啶藥物應用於癌症治療
TW104134954A TW201615222A (zh) 2014-10-24 2015-10-23 免疫疾病用藥臨床新應用
TW104134961A TW201615193A (zh) 2014-10-24 2015-10-23 帕羅西汀藥物應用於癌症治療
TW104134924A TW201615218A (zh) 2014-10-24 2015-10-23 心血管疾病藥物臨床新應用
TW104134945A TW201615188A (zh) 2014-10-24 2015-10-23 奈必洛爾藥物應用於癌症治療
TW104134952A TW201615221A (zh) 2014-10-24 2015-10-23 炎症用藥臨床新應用
TW104134964A TW201615225A (zh) 2014-10-24 2015-10-23 內分泌疾病用藥臨床新應用
TW104134933A TWI652060B (zh) 2014-10-24 2015-10-23 阿折地平藥物應用於癌症治療
TW104134928A TW201615197A (zh) 2014-10-24 2015-10-23 蘋果酸丙氯陪拉辛錠藥物應用於癌症治療
TW104134908A TWI672150B (zh) 2014-10-24 2015-10-23 抗生素藥物臨床新應用
TW104134963A TW201615224A (zh) 2014-10-24 2015-10-23 消化系統疾病用藥臨床新應用
TW104134965A TW201615226A (zh) 2014-10-24 2015-10-23 代謝性疾病藥物臨床新應用

Family Applications Before (20)

Application Number Title Priority Date Filing Date
TW104134942A TW201615195A (zh) 2014-10-24 2015-10-23 阿那格雷藥物應用於癌症治療
TW104134956A TW201615196A (zh) 2014-10-24 2015-10-23 山喜多藥物應用於癌症治療
TW104134959A TW201615223A (zh) 2014-10-24 2015-10-23 驅蟲藥臨床新應用
TW104134960A TW201615191A (zh) 2014-10-24 2015-10-23 氨氯地平藥物應用於癌症治療
TW104134936A TWI621434B (zh) 2014-10-24 2015-10-23 千憂解藥物應用於癌症治療
TW104134944A TW201615219A (zh) 2014-10-24 2015-10-23 呼吸系統疾病用藥臨床新應用
TW104134950A TWI663969B (zh) 2014-10-24 2015-10-23 莫諾苯宗藥物應用於癌症治療
TW104134946A TWI663984B (zh) 2014-10-24 2015-10-23 神經疾病用藥臨床新應用
TW104134940A TW201615186A (zh) 2014-10-24 2015-10-23 脫克鈣藥物應用於癌症治療
TW104134966A TW201615194A (zh) 2014-10-24 2015-10-23 氨苯蝶啶藥物應用於癌症治療
TW104134954A TW201615222A (zh) 2014-10-24 2015-10-23 免疫疾病用藥臨床新應用
TW104134961A TW201615193A (zh) 2014-10-24 2015-10-23 帕羅西汀藥物應用於癌症治療
TW104134924A TW201615218A (zh) 2014-10-24 2015-10-23 心血管疾病藥物臨床新應用
TW104134945A TW201615188A (zh) 2014-10-24 2015-10-23 奈必洛爾藥物應用於癌症治療
TW104134952A TW201615221A (zh) 2014-10-24 2015-10-23 炎症用藥臨床新應用
TW104134964A TW201615225A (zh) 2014-10-24 2015-10-23 內分泌疾病用藥臨床新應用
TW104134933A TWI652060B (zh) 2014-10-24 2015-10-23 阿折地平藥物應用於癌症治療
TW104134928A TW201615197A (zh) 2014-10-24 2015-10-23 蘋果酸丙氯陪拉辛錠藥物應用於癌症治療
TW104134908A TWI672150B (zh) 2014-10-24 2015-10-23 抗生素藥物臨床新應用
TW104134963A TW201615224A (zh) 2014-10-24 2015-10-23 消化系統疾病用藥臨床新應用

Country Status (9)

Country Link
US (7) US10105357B2 (zh)
EP (3) EP3222278B1 (zh)
JP (1) JP6539345B2 (zh)
KR (1) KR102490334B1 (zh)
CN (3) CN107106550A (zh)
AU (2) AU2015335375B2 (zh)
ES (1) ES2954860T3 (zh)
TW (21) TW201615195A (zh)
WO (21) WO2016062272A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663969B (zh) * 2014-10-24 2019-07-01 朗齊生物醫學股份有限公司 莫諾苯宗藥物應用於癌症治療

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
PL3236967T3 (pl) 2014-12-22 2020-04-30 Suda Pharmaceuticals Ltd Zapobieganie i leczenie przerzutów u pacjentów z nadpłytkowością typu nowotworowego
WO2017116049A1 (ko) * 2015-12-31 2017-07-06 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 치료 및 전이 억제용 약학적 조성물
EP3241562A1 (en) * 2016-05-02 2017-11-08 Fundació Institut Mar d'Investigacio Medica Zonisamide for use in the treatment of breast cancer
CN106074474A (zh) * 2016-06-15 2016-11-09 中南大学湘雅医院 羟苄丝肼及其在药学上可接受的盐在制备抗肿瘤药物方面的应用
WO2018072135A1 (zh) * 2016-10-19 2018-04-26 微菌方舟生物科技股份有限公司 二氢吡啶类钙拮抗剂用于治疗癌症的用途
CN108066345A (zh) * 2016-11-14 2018-05-25 武汉华杰世纪生物医药有限公司 一种具有抗肿瘤作用的化合物
WO2018115001A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
BR112019012573A2 (pt) 2016-12-20 2019-11-19 Lts Lohmann Therapie Systeme Ag sistema terapêutico transdérmico que contém asenapina e polissiloxano ou poli-isobutileno
US20200179404A1 (en) * 2017-06-09 2020-06-11 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
WO2019008516A2 (en) * 2017-07-03 2019-01-10 Menri Group Ltd. TREATMENT OF CANCER WITH DIHYDROPYRIDINES
JP2019064976A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
KR101933805B1 (ko) 2017-10-17 2018-12-28 성균관대학교산학협력단 옥셀라딘시트레이트를 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학적 조성물
CN108186652A (zh) * 2017-12-28 2018-06-22 深圳大学 缝隙连接细胞间通迅抑制剂甘珀酸在制备预防和治疗肝细胞癌药物中的应用
AU2019214891A1 (en) 2018-01-30 2020-08-20 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
WO2019204764A1 (en) * 2018-04-19 2019-10-24 Washington University Compositions and methods of use thereof for treatment of proteinopathies
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
FR3090084B1 (fr) 2018-12-18 2023-10-13 Securengy Projectile pour armes à feu ou air comprimé pour emport liquide ou pulvérulent.
WO2020132253A1 (en) * 2018-12-19 2020-06-25 University Of Vermont And State Agricultural College Cancer therapeutic compositions and methods
US20220193020A1 (en) * 2019-04-04 2022-06-23 Daegu-Gyeongbuk Medical Innovation Foundation Pharmaceutical Composition Comprising Trimebutine or Pharmaceutically Acceptable Salt Thereof as an Active Ingredient For Prevention or Treatment of Cancer
US20220202771A1 (en) * 2019-04-05 2022-06-30 University Of North Texas Health Science Center At Fort Worth Antidepressants for the Treatment or Prevention of Memory Loss and/or Cognitive Decline or Dysfunction in Aging
WO2020210643A1 (en) * 2019-04-11 2020-10-15 Ian Basil Shine Cell membrane permeability restoring therapy
CN110179803A (zh) * 2019-05-31 2019-08-30 天津科技大学 一种噻吨溴类化合物的应用
CN110742890A (zh) * 2019-10-24 2020-02-04 暨南大学 洛美利嗪在制备抗结肠癌药物中的应用
CN110840887A (zh) * 2019-11-18 2020-02-28 杭州彗搏科技有限公司 三氯苯达唑在制备治疗乳腺癌的药物中的应用
CN110876800B (zh) * 2019-11-18 2023-06-27 中南大学 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN111067899B (zh) * 2020-01-08 2021-03-05 温州医科大学 一种抗疟药物磷酸伯氨喹在制备治疗白血病药物上的应用
US11304969B2 (en) * 2020-01-24 2022-04-19 The Florida International Univeristy Board Of Trustees Treatments of prostate cancer
CN111973593A (zh) * 2020-05-09 2020-11-24 深圳市罗湖区人民医院 硝唑尼特及其药学上可接受的盐在制备治疗膀胱癌药物中的用途
CN111557941A (zh) * 2020-06-15 2020-08-21 浙江大学 Plod2的小分子抑制剂米诺地尔在肿瘤治疗中的应用
CN111848717A (zh) * 2020-08-07 2020-10-30 四川大学 靶向调控线粒体能量代谢的化合物及其应用和药物
WO2022033465A1 (zh) * 2020-08-10 2022-02-17 萧乃文 具有协同抗癌功效的氯硝柳胺和双硫仑医药组合物及其用途
CN112274525B (zh) * 2020-12-04 2022-04-08 遵义医科大学 一种化疗药物组合物及其应用
CN112336725A (zh) * 2020-12-11 2021-02-09 吴照球 甲氧苄啶的医药新用途
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
CN112569215A (zh) * 2020-12-30 2021-03-30 东莞市人民医院 度米芬在制备防治结直肠癌的药物中的应用
EP4108244A1 (en) * 2021-06-25 2022-12-28 Universität Regensburg Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
CN113663071B (zh) * 2021-06-28 2022-12-30 四川大学 Fbxl2激活剂在制备治疗egfr驱动的肺癌的药物中的用途
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
WO2023035200A1 (zh) * 2021-09-09 2023-03-16 中国福利会国际和平妇幼保健院 五氟利多在制备治疗子宫内膜癌的药物中的应用
CN115887455B (zh) * 2022-08-04 2024-04-05 北京大学人民医院 钙离子通道阻滞剂阿折地平在制备治疗子宫内膜癌的药物中的应用
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2150942C1 (ru) * 1993-10-01 2000-06-20 Синтекс (Ю.ЭС.ЭЙ.) Инк. Оральные суспензии, содержащие высокие дозы мофетила микофенолята
KR100264348B1 (ko) * 1994-12-28 2000-08-16 디르크 반테 항-죽종형성제로서 네비볼롤을 함유하는 조성물
ATE449603T1 (de) * 1998-09-15 2009-12-15 Lilly Co Eli Verwendung von duloxetine zur behandlung von fibromyalgie
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
US6846939B2 (en) * 2000-07-07 2005-01-25 Paratek Pharmaceuticals, Inc. 9-substituted minocycline compounds
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
RU2006112834A (ru) * 2003-09-18 2007-10-27 Комбинаторкс, Инкорпорейтед (Us) Сочетание лекарственных средств для лечения новообразований
OA13284A (en) * 2003-11-06 2007-01-31 Corporation Celgene Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases.
JP2007537246A (ja) * 2004-05-12 2007-12-20 バイオランクス カンパニー リミテッド ニコチン酸誘導体を有効成分として含む癌予防及び治療剤
KR101336462B1 (ko) * 2004-05-21 2013-12-04 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 테트라사이클린 및 이의 유사체의 합성
CN1279980C (zh) * 2004-10-14 2006-10-18 孔庆忠 一种抗实体肿瘤药物组合物
JP2006298781A (ja) * 2005-04-15 2006-11-02 Geno Membrane:Kk エストロン３硫酸トランスポーター活性阻害剤
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CN101223149A (zh) * 2005-07-05 2008-07-16 特瓦制药工业有限公司 制备缬沙坦的方法
SI1909778T1 (en) * 2005-07-28 2018-07-31 Academisch Ziekenhuis bij de Universiteit van Amsetrdam MONOFENOLNE, BENZENDIOLE OR SULFHYDRYAL COMPOUNDS FOR THE USE IN THE TREATMENT OF MELANOMS
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
EP2001832A1 (en) * 2006-03-23 2008-12-17 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
CN101099724A (zh) * 2006-07-07 2008-01-09 上海复旦复华药业有限公司 一种微粉化来曲唑及其组合物
CN101103976A (zh) * 2006-07-14 2008-01-16 海南盛科生命科学研究院 一种含阿那曲唑的口服药物组合物及其制备工艺
EP2114399A2 (en) * 2007-01-05 2009-11-11 Cornerstone Therapeutics Inc. R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma)
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
EP2170805B1 (en) * 2007-06-21 2016-03-16 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
WO2009025854A1 (en) * 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CN100563645C (zh) * 2007-12-06 2009-12-02 济南帅华医药科技有限公司 一种治疗实体肿瘤的蓓萨罗丁缓释植入剂
US20090270397A1 (en) * 2008-04-08 2009-10-29 Orlow Seth J Methods and compositions for the treatment of cancers, such as melanomas and gliomas
CN101569624A (zh) * 2008-04-29 2009-11-04 石药集团中奇制药技术（石家庄）有限公司 氨氯地平在制备治疗细胞增生性疾病药物中的用途
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
CN101991553B (zh) * 2009-08-21 2015-02-25 北京以岭生物工程技术有限公司 一种依西美坦片及其制备方法
CN101863806B (zh) * 2010-03-18 2013-02-13 湖北省医药工业研究院有限公司 抗前列腺癌药物(r)-比卡鲁胺的制备方法
US9012511B2 (en) * 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
WO2012015023A1 (ja) * 2010-07-29 2012-02-02 国立大学法人京都大学 抗がん剤のスクリーニング方法
CN103429235A (zh) * 2010-12-15 2013-12-04 赖鸿政 用于治疗癌症的化合物及其应用
CN102631354B (zh) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 含维生素d3和二甲双胍的药物组合物
CN102688493B (zh) * 2011-03-25 2014-09-10 鼎泓国际投资（香港）有限公司 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用
CN102813643B (zh) * 2011-06-10 2014-09-24 北京蛋白质组研究中心 bumetanide在抑制肝癌细胞转移中的应用
WO2013049045A1 (en) * 2011-09-27 2013-04-04 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
CN109985228A (zh) * 2011-11-10 2019-07-09 凯伊药品公司 拟钙剂及其使用方法
ES2384069B1 (es) * 2012-03-29 2013-07-04 Hospital Sant Joan De Déu Cinacalcet y tumores neuroblásticos
CN102600077B (zh) * 2012-03-29 2013-06-05 江苏豪森药业股份有限公司 吉西他滨或其盐纳米乳剂注射液及其制备方法
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014036654A1 (en) * 2012-09-06 2014-03-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
WO2014046983A1 (en) * 2012-09-21 2014-03-27 Intensity Therapeutic Method of treating cancer
SI2903616T1 (en) * 2012-10-04 2018-02-28 Ab Science The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease
CN103356687B (zh) * 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
US9622982B2 (en) * 2013-01-14 2017-04-18 Health Clinics Limited Cancer drug and uses
CN103933569B (zh) * 2013-01-22 2017-01-11 复旦大学 一种抗肺癌药物组合物及其应用、药盒和包装件
US9890127B2 (en) * 2013-03-11 2018-02-13 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
CN104161759B (zh) * 2013-05-16 2019-10-08 中国科学院上海药物研究所 阿那格雷及其衍生物的抗肿瘤用途
CN103396419A (zh) * 2013-08-13 2013-11-20 海宁市绿升医药科技有限公司 肿瘤光动力治疗药二氢卟吩e6-15-乙酯及其制备方法
CN103536925B (zh) * 2013-10-28 2015-07-01 中国医学科学院基础医学研究所 强心苷化合物在非小细胞肺癌治疗中的应用
CN103622975B (zh) * 2013-11-07 2016-06-15 广东药学院 格列吡嗪在制备治疗肿瘤药物中的应用
CA2979530C (en) * 2014-04-08 2023-10-03 The Methodist Hospital Inos-inhibitory compositions and their use as breast cancer therapeutics
WO2016062272A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 免疫疾病用药物在制备抑制癌症的医药组合物中的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663969B (zh) * 2014-10-24 2019-07-01 朗齊生物醫學股份有限公司 莫諾苯宗藥物應用於癌症治療

Also Published As

Publication number Publication date
AU2015335375A1 (en) 2017-05-18
EP3222278A4 (en) 2018-06-20
EP3210604A4 (en) 2018-06-27
TW201615220A (zh) 2016-05-01
WO2016062279A1 (zh) 2016-04-28
US20170304387A1 (en) 2017-10-26
EP3210604C0 (en) 2024-02-14
TW201615186A (zh) 2016-05-01
TW201615184A (zh) 2016-05-01
WO2016062290A1 (zh) 2016-04-28
EP3235497A1 (en) 2017-10-25
TW201615219A (zh) 2016-05-01
EP3222278C0 (en) 2023-06-14
ES2954860T3 (es) 2023-11-27
WO2016062286A1 (zh) 2016-04-28
WO2016062267A1 (zh) 2016-04-28
TW201615197A (zh) 2016-05-01
EP3222278B1 (en) 2023-06-14
US20170304286A1 (en) 2017-10-26
WO2016062281A1 (zh) 2016-04-28
US20170216247A1 (en) 2017-08-03
TW201615194A (zh) 2016-05-01
WO2016062265A1 (zh) 2016-04-28
TWI672150B (zh) 2019-09-21
WO2016062266A1 (zh) 2016-04-28
CN107106523A (zh) 2017-08-29
WO2016062278A1 (zh) 2016-04-28
TW201615189A (zh) 2016-05-01
WO2016062289A1 (zh) 2016-04-28
AU2015335391A1 (en) 2017-06-01
CN106999470A (zh) 2017-08-01
TW201615217A (zh) 2016-05-01
TWI663969B (zh) 2019-07-01
AU2015335375B2 (en) 2020-09-10
WO2016062287A1 (zh) 2016-04-28
TWI652060B (zh) 2019-03-01
WO2016062288A1 (zh) 2016-04-28
CN107106550A (zh) 2017-08-29
US10098852B2 (en) 2018-10-16
WO2016062272A1 (zh) 2016-04-28
US20170312260A1 (en) 2017-11-02
EP3210604B1 (en) 2024-02-14
KR102490334B1 (ko) 2023-01-18
TW201615222A (zh) 2016-05-01
TW201615195A (zh) 2016-05-01
US20170304218A1 (en) 2017-10-26
WO2016062270A1 (zh) 2016-04-28
EP3235497A4 (en) 2018-06-13
WO2016062269A1 (zh) 2016-04-28
TW201615193A (zh) 2016-05-01
US20170304388A1 (en) 2017-10-26
JP6539345B2 (ja) 2019-07-03
JP2017532351A (ja) 2017-11-02
TW201615224A (zh) 2016-05-01
EP3210604A1 (en) 2017-08-30
AU2015335391B2 (en) 2018-06-21
US10045962B2 (en) 2018-08-14
WO2016062291A1 (zh) 2016-04-28
WO2016062277A1 (zh) 2016-04-28
WO2016062285A1 (zh) 2016-04-28
TW201615191A (zh) 2016-05-01
TW201615225A (zh) 2016-05-01
TW201615218A (zh) 2016-05-01
US10105357B2 (en) 2018-10-23
US20170304228A1 (en) 2017-10-26
WO2016062275A1 (zh) 2016-04-28
WO2016062271A1 (zh) 2016-04-28
WO2016062283A1 (zh) 2016-04-28
TW201615196A (zh) 2016-05-01
TWI621434B (zh) 2018-04-21
TW201615223A (zh) 2016-05-01
EP3222278A1 (en) 2017-09-27
TW201615221A (zh) 2016-05-01
TW201615188A (zh) 2016-05-01
KR20170084034A (ko) 2017-07-19
TWI663984B (zh) 2019-07-01
WO2016062274A1 (zh) 2016-04-28
TW201615192A (zh) 2016-05-01

Similar Documents

Publication Publication Date Title
TW201615226A (zh) 代謝性疾病藥物臨床新應用
JP2011522773A5 (zh)
CN105120876A (zh) 癌症的治疗
CN102065865A (zh) 多发性骨髓瘤治疗
EP3445366A1 (en) Method of treating liver cancer
WO2019090141A1 (en) Combination drug therapies for cancer and methods of making and using them
US9901602B2 (en) Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
Stathopoulos et al. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects
Soares et al. The combination of Cl-IB-MECA with paclitaxel: A new anti-metastatic therapeutic strategy for melanoma
CN1615136A (zh) 包含埃坡霉素和抗代谢物的组合
Ninomiya et al. Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non–Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol
CN104434948B (zh) 一种抗胰腺癌的药物组合物及其应用
CN113893256A (zh) 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用
CN113893351A (zh) 组合物及其在制备治疗癌症的药物中的应用
Lee et al. Effectiveness of tumor‑treating fields to reduce the proliferation and migration of liposarcoma cell lines
CA3090748A1 (en) Methods and combination therapy to treat biliary tract cancer
RU2456006C1 (ru) Способ лечения больных туберкулезом легких
Porta et al. Medical treatment of advanced hepatocellular carcinoma patients: the issue is not the right drug, but the right patient
RU2329803C1 (ru) Способ лечения туберкулеза легких
Bakuridze et al. FORMULATION AND TECHNOLOGY OF TARGETED DELIVERY AND MODIFIED-RELEASE SYSTEMS
Doppalapudi et al. Assessment of the Effect of Bromelain on Glucose Uptake Using Everted Gut Sac Technique
WO2023031798A1 (en) Dosing regimen for a tead inhibitor
CN1774249A (zh) 伊立替康在治疗耐受性乳腺癌中的应用
Polyzos et al. Double biochemical modulation of 5-fluorouracil by methotrexate and folinic acid for the treatment of advanced colorectal cancer